Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

187 results about "Immune therapy" patented technology

Immunotherapy, also called biological therapy, is a type of treatment that uses the body's immune system to fight cancer. The therapy mainly consists of stimulating the immune system to help it do its job more effectively. Immunotherapy is a comparatively new type of therapy in the fight against many cancers.

Tumor antigen peptide and use thereof

PCT designated stage expiredWO2025108140A1Genetically modified cellsNucleic acid vectorIn vitro stimulationImmune therapy
The present application relates to the field of biomedicine, and in particular to a tumor antigen peptide and a use thereof. Provided is a tumor antigen peptide, comprising a peptide segment having an amino acid sequence as shown in SEQ ID NO: 1. The provided tumor antigen peptide can be presented by the HLA subtype (HLA-A*11:01) having a high proportion of Chinese population. Additionally, by means of in vitro stimulation, the tumor antigen peptide is verified to effectively stimulate specific T cells, and a specific TCR element is successfully obtained. The present application lays a direct foundation for further developing TCR-T therapy targeting human TP53 R248Q and immunotherapy such as therapeutic vaccines.
Owner:SHANGHAI FIRST PEOPLES HOSPITAL +1

ZIF-8 nano-particles loaded with mitoxantrone, preparation and application of ZIF-8 nano-particles in tumor chemical-immunotherapy

The invention relates to the technical field of medicines, and provides mitoxantrone-loaded ZIF-8 nanoparticles, a preparation method thereof and an application of the mitoxantrone-loaded ZIF-8 nanoparticles in tumor chemical-immunotherapy. Aiming at the defects of combined chemotherapy and immunotherapy clinically at the present stage, MIT ZIF-8 synthesized by a normal-temperature full-water-phase one-pot method is used as a novel chemical-immunotherapy scheme, and the capability of inducing cell immunogenic death of a chemotherapeutic drug mitoxantrone is enhanced by utilizing pyroptosis; the anti-tumor immune activation capability is enhanced while tumor cells are killed through chemotherapy, effective chemical-immune therapy is achieved, and the responsiveness of tumors to immune checkpoint inhibitor therapy is enhanced.
Owner:FUDAN UNIV SHANGHAI CANCER CENT

Histamine and HRH1 signaling activity as biomarkers and associated methods

A method of determining the likelihood that a subject with cancer will respond to an immunotherapy comprising a checkpoint inhibitor. The method comprises detecting the level of histamine in a biological sample obtained from the subject. Subjects determined to have a low likelihood of responding to the immunotherapy can be administered an alternative therapy or administered an antihistamine in conjunction with the immunotherapy. Methods of treating cancer patients are also provided, as are kits and systems for histamine detection, recordation, and responder status determination.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Natural killer cells for chordoma therapy

Provided herein are methods and compositions for treating chordoma by preferentially targeting cancer stem cells than non-cancer stem cells in chordoma to effectively treat chordoma. In some embodiments, the chordoma tumors cells (preferentially the cancer stem cells in chordoma) are targeted by modified NK-92 cells (i.e., haNK® cells) that express CARs that comprise means for binding to the PD-L1 and another tumor-specific antigen (e.g., EGFR). In some embodiments, the chordoma tumor cells are targeted by using NK cells in combination with a means for binding to means for binding to the PD-L1 and / or a means for binding another tumor antigen (e.g., EGFR). Each of the treatment methods disclosed above may be implemented prior to, and / or concurrent with radio- and / or chemotherapy, and / or may be employed with immune therapy as is discussed in more detail below.
Owner:IMMUNITYBIO INC

Immunogenic composition for the treatment of cancer

The invention relates to the field of immunotherapy, more in particular to a composition for use in the treatment of cancer. The invention also relates to a composition obtainable by such a method, such as a pharmaceutical composition. More in particular, the invention relates to an ex vivo method for obtaining a composition suitable for the treatment of cancer in a subject, comprising the steps of providing primary tumor cells derived from the subject, and ex vivo contacting the tumor cells with an inhibitor of a bromodomain and extra-terminal domain family member (BET inhibitor).
Owner:APGEN THERAPEUTICS AB

Tumor nano vaccine of bionic autophagosome as well as preparation method and application of tumor nano vaccine

The invention discloses a tumor nano vaccine (BAPs) of bionic autophagosome as well as a preparation method and application thereof, and the vaccine effectively stimulates anti-tumor immunity by precisely fusing a neoantigen derived from the autophagosome and an immunologic adjuvant targeted lymph node. The BAPs with the redox response characteristic promote the vaccine to be opened in antigen presenting cells, so that an adjuvant and an antigen are exposed, and a strong immune response is stimulated. The BAPs can excite wide T cell reactions, and finally, more than 70% of established tumors are effectively eliminated. BAPs vaccination initiates a lasting T cell reaction and provides powerful protection, all mice are protected in tumor recurrence challenge, and the tumor incidence rate is significantly reduced by nearly 90%. In addition, the BAPs and a checkpoint inhibition therapy have a synergistic effect, and growth of breast cancer with poor immunogenicity is inhibited. The BAPs nano vaccine provides an efficient strategy with clinical transformation potential to enhance the strong immune response of personalized cancer immunotherapy.
Owner:SUZHOU UNIV

Alkaline extraction of beta glucan compounds for use in Anti-viral and immune therapies

InactiveUS20240408196A1Organic active ingredientsMicroorganism based processesAdjuvantImmune related genes
A method of extracting beta-glucan from autolyzed yeast material comprises a pre-wash step with water, an alkaline wash extraction step, a post-wash step with water, and if necessary, a drying step (e.g., spray-drying), with a dewatering and centrifugation between each step. The extraction improves efficiency by skipping the acidic and organic washes common to beta-glucan extraction. It has been discovered that beta glucan products yielded from this process have improved immunological properties, stimulating the expression of several immune-related genes in human macrophages without corresponding levels of stimulation for inflammatory pathways. The resulting beta glucan product can be administered as a supplement or adjuvant to existing anti-viral therapies.
Owner:JORDAN FRANK +3

Small molecule metabolites as predictors and mediators of immune response and immune therapy response

Methods are disclosed related to identifying small molecule metabolites that serve as biomarkers of immune related adverse events (irAEs). In embodiments, treatments are disclosed that reduce the likelihood or prevent irAEs.
Owner:LA JOLLA INST FOR IMMUNOLOGY

Biomarker comprising lactobacillus salivarius or bacteroides flavius for responsive prediction and prognosis of immune anticancer drug treatment, and method for responsiveness prediction and prognosis of immune anticancer drug treatment using same

The present invention. relates to a biomarker comprising Lactobacillus salivarius or Bacteroides flavius for responsiveness prediction and prognosis of immune anticancer drug treatment and a method for responsiveness prediction and prognosis of immune anticancer drug treatment using same. In the present invention, Lactobacillus salivarius and Bacteroides plebeius strains were selected as strains that inhibit the therapeutic effect of immune anticancer agents in a cohort of patients treated with immune anticancer agents who have received fecal microorganism transplantation. By detecting the strain, the present invention has the effects of predicting immune anticancer drug treatment responsiveness or prognosis after immune anticancer drug treatment and securing the efficiency of existing fecal microorganism transplantation. In addition, the selected strain is a strain present in the human intestine and has excellent safety due to low therapeutic side effects, and thus is expected to be advantageously used for treatment of autoimmune diseases and the like through immune activity inhibition.
Owner:THE ASAN FOUND +2

Identification of immunogenic mutant peptides using genomic, transcriptomic and proteomic information

The present disclosure provides methods of identifying a disease-specific immunogenic peptide through a series of selection steps. Immunogenic epitopes identified by methods of the present disclosure are applicable for use in peptide-based immunotherapy, preferably cancer therapy. Furthermore, the methods of the present disclosure may be performed in a high-throughput manner and serve as a means of personalized vaccine development and therapy. Also provided are compositions of immunogenic peptides as well as methods of treatment comprising said compositions.
Owner:GENENTECH INC

Combination tumor immunotherapy

Provided are methods for treating cancer using local administration of certain CpG oligonucleotides (CpG ODN) and systemic administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and / or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-α) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.
Owner:CHECKMATE PHARM INC

Catequentinib (anlotinib) in sequential combination with immunotherapy for use in the treatment of cancer

The present invention relates to a chemo combination therapy regimen to treat cancer. More specifically, the present invention relates to a novel chemo combination therapy regimen which relates to the combination of compound AL3818 (anlotinib, catequentinib) or its pharmaceutically acceptable salts with standard platinum-based and other chemotherapy agents or immunotherapy agents. The combination of these agents should be able to provide higher efficacy than employing any agent individually.
Owner:ADVENCHEN LABORATORIES LLC

Combination immunotherapy and antiviral treatment

PCT designated stage expiredWO2025050047A1Viral antigen ingredientsAntiviralsImmune therapyT cell
The present invention relates generally to the combination of immunotherapy and antiviral treatment for the treatment or prevention of HIV. In particular, the methods include in vivo and / or ex vivo enrichment of HIV-specific CD4+ T cells.
Owner:AMERICAN GENE TECHNOLOGIES INTERNATIONAL INC

Methods and compositions for treating cancer

Provided herein are methods of treating or ameliorating an immune-related adverse event associated with an immunotherapy or immune-modulating therapy in a subject with cancer, autoimmune disease or other condition requiring immune-modulating agents, the method comprising administering to the subject an agent that modulates the activity or expression of TIGIT.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE +6

Multi-mode brain-targeted intelligent nano-drug system aiming at brain glioma and preparation method of multi-mode brain-targeted intelligent nano-drug system

The invention discloses a multi-mode brain-targeted intelligent nano-drug system aiming at brain glioma and a preparation method of the multi-mode brain-targeted intelligent nano-drug system. According to the system, a dual enhancer MnO2 nanoparticle capable of combining a chemodynamic therapy and an immunotherapy is loaded with a traditional chemotherapeutic drug doxorubicin hydrochloride to serve as an inner core, and the outer layer is coated with a bionic lipid membrane with vitamin D3 and a neutrophile granulocyte membrane. According to the system, the inflammation chemotaxis and adhesion capacity of bionic neutrophil are utilized, specific delivery of glioma is achieved, manganese dioxide is further reduced into divalent manganese ions by responding to glutathione (GSH) in the tumor microenvironment in the glioma microenvironment, doxorubicin hydrochloride and vitamin D3 are released, finally cGAS-STING immune response is synergistically activated, and the glioma is specifically delivered. The compound can promote tumor cell apoptosis and reverse glioma immunosuppression microenvironment, and is especially used for multi-mode combined treatment of brain glioma.
Owner:JIANGYIN PEOPLES HOSPITAL +1

Hepatocellular carcinoma prognosis and immune response prediction method based on multi-omics machine learning

The invention discloses a hepatocellular carcinoma prognosis and immune response prediction method based on multi-omics machine learning, and relates to the technical field of biomedicine and artificial intelligence crossing, and the method comprises the following steps: S1, constructing a multi-omics data set for model training and verification; s2, performing feature integration and clustering analysis on the multi-omics data to obtain corresponding hepatocellular carcinoma molecular subtype distribution; s3, constructing a hepatocellular carcinoma prognosis model based on Cox regression combined with a random survival forest, identifying 11 core immune genes and corresponding weight coefficients by training the model, and constructing an immunotherapy response index IMLIRI score; and S4, carrying out clinical application on the IMLIRI score. According to the method, through multi-omics data integration and multi-queue external verification, the influence of data deviation and queue heterogeneity on the model performance is reduced, so that the method shows stable prediction performance in hepatocellular carcinoma queues with different sources and different pathogenesis backgrounds, and the reliability and generalizability of the model in clinical application are improved.
Owner:CHENGDU UNIV OF TRADITIONAL CHINESE MEDICINE

Combination of urolithin and immunotherapy treatments

The present invention relates to a combination of urolithin and immunotherapy treatments, in particular a combination of urolithin and a therapeutic agent, in particular a combination of urolithin and immunotherapy treatments, such as a PD-1 antagonist, and an immune checkpoint blocking therapy. The invention also relates to pharmaceutical compositions comprising said combination, processes for the preparation of said pharmaceutical compositions and methods of using said compositions in the treatment of disease. In one embodiment, the immune checkpoint blocking therapy is selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA4 antibody, or a fusion protein.
Owner:AMAZENTIS SA

An immune scoring prediction method for advanced lung cancer

The present invention discloses a method for predicting the immune score of advanced lung cancer. The method comprises: obtaining slice image data of biological tissue of a patient to be predicted for lung cancer; improving the quality of the slice image data based on a neural network algorithm to obtain optimized image data; inputting the optimized image data into a feature extraction model to obtain a corresponding image feature vector; inputting the image feature vector into a trained immune therapy score prediction neural network to obtain the corresponding immune therapy effect of the patient to be predicted for lung cancer; the immune therapy score prediction neural network is trained using a training data set including multiple training tissue slice images and corresponding immune therapy score annotations. It can be seen that the present invention can achieve accurate immune therapy prediction directly based on images, reduce prediction costs, and improve prediction efficiency and accuracy.
Owner:SUN YAT SEN UNIVERSITY CANCER CENTER (CANCER HOSPITAL AFFILIATED TO SUN YAT SEN UNIVERSITY CANCER RESEARCH INSTITUTE OF SUN YAT SEN UNIVERSITY) +1

Method and kit for evaluating mast cell polarization typing

The invention discloses application of a mast cell polarization typing detection kit, and belongs to the field of biological medicine. The kit comprises a mast cell characteristic enzyme TPSB2 detection reagent, and one or more of a mast cell MC1 type polarization detection reagent and a mast cell MC2 type polarization detection reagent, the MC1 type polarization is CCL27, and the expression of TNF-alpha is up-regulated; and the MC2 type polarization comprises expression up-regulation of CCL3, IL-16 and VEGFA (vascular endothelial growth factor A). Mstoma cells have dual effects in a tumor microenvironment, can promote tumor progression, and also can enhance anti-tumor immune response. The mastocyte polarization typing is identified through the expression level of the biomarker, so that the mastocyte polarization typing can be rapidly and accurately evaluated, identification indexes and tools are provided for further discussing the functions of mastocytes in different polarization states, cancer diagnosis can be assisted, the onset risk of cancer can be reduced, and the method is suitable for popularization and application. And an immunotherapy target is provided for clinical treatment of cancers.
Owner:NORTH CHINA PETROLEUM BUREAU GENERAL HOSPITAL +1

1-Aminobenzo[4,5]imidazo[1,2]pyrazine-3-formamide compounds and their preparation and use

The present invention belongs to the technical field of medicinal chemistry. Specifically, the present invention discloses a 1-aminobenzo[4,5]imidazo[1,2]pyrazine-3-formamide compound and its preparation and use. The compound of the present invention has a structure represented by formula (I). The compound has a novel structure and is a kind of adenosine receptor inhibitor. It has excellent inhibitory activity against adenosine A2A receptor and good subtype selectivity. It can inhibit adenosine A2A receptor and has adenosine A2A receptor and ... 2A Adenosine A is used in immunotherapy as a receptor-targeting inhibitor. 2A By inhibiting the activity of the receptor, the immune system can release the tumor cell rejection function, thereby playing a role in treating tumors. At the same time, the compound of the present invention is easy to prepare, uses inexpensive compounds as raw materials, has mild reaction conditions, has high total yield and purity, and can be produced on a scale of several tens of grams, making it suitable for use in the subsequent clinical trials of adenosine A 2A This will be useful in researching potential receptor inhibitors. [C70] TIFF2025503599000074.tif35170
Owner:SUN YAT SEN UNIV

Methods and compositions comprising tumor suppressor gene therapy and CD122 / CD132 agonists for the treatment of cancer

Provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of at least one CD122 / CD132 agonist, at least one immune checkpoint inhibitor and a viral composition comprising one or more viruses engineered to overexpress a tumor suppressor gene and / or an adenoviral death protein. Also provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of at least one oncolytic viral composition and at least one CD122 / CD132 agonist and at least one immune checkpoint inhibitor. Also provided herein are methods of enhancing anti-tumor efficacy by administering the agents described above in combination with other cancer therapies. In highly aggressive forms of cancer, known to be generally resistant to immune therapies, these treatments unexpectedly resulted in complete tumor remissions and curative outcomes.
Owner:MULTIVIR INC

Improving efficacy and persistent response of immunotherapy

Provided herein are methods for preparing, producing, processing, culturing, isolating or manufacturing cells suitable for immune or cell therapy and their use in cell therapy. Further provided are methods of treating cancer patients with such cells.
Owner:KITE PHARMA INC

Biomarkers associated with checkpoint immune therapy and methods of using same

Provided herein are methods for treating cancer in a subject comprising administering an ICB therapy to a subject having cancer, wherein the subject's cancer comprises one or more mutations in two or more genes associated with responsiveness to immune checkpoint blockade (ICB).
Owner:DUKE UNIV

Method and system for analyzing immune cell change of HER2 variant lung cancer patient

The invention discloses a method and a system for analyzing immune cell change of an HER2 variant lung cancer patient. The method comprises the following steps: collecting a peripheral blood sample and carrying out single-cell RNA (Ribonucleic Acid) sequencing; performing quality control, standardization processing, dimensionality reduction and clustering analysis on the sequencing data; carrying out immune cell subset annotation on the clustering result based on a preset immune cell marker; analyzing cell communication modes among different immune cell subpopulations by using a ligand-receptor database; performing quantitative statistics on the proportion of various immune cells based on sample grouping; and further performing subpopulation fine analysis, quasi-time sequence trajectory reconstruction and metabolic pathway activity evaluation on the CD8 + T cells to construct a comprehensive immune cell map. According to the method, the multi-dimensional characteristics of the peripheral blood immune cells can be presented at high resolution, and the comprehensive analysis of the functional state, the communication network and the metabolic activity of the immune cells is realized. According to the system and the device, automatic operation and visual display of the method can be realized. According to the invention, the immune monitoring efficiency can be improved, and an effective tool is provided for immune treatment effect evaluation and disease mechanism research.
Owner:SHANGHAI PULMONARY HOSPITAL (SHANGHAI OCCUPATIONAL DISEASE PREVENTION & CONTROL INSTITUTE)

Signatures for predicting cancer immune therapy response

PendingUS20260063636A1Health-index calculationMicrobiological testing/measurementMolecular classificationOncology
This disclosure generally relates to a molecular classification of cancer and particularly to molecular markers for predicting response to cancer therapy, including cancer immune therapy, and methods of use thereof.
Owner:MYRIAD GENETICS INC

Systems and methods for histotripsy immunosensitization

To provide systems and methods for histotripsy and immune therapies.SOLUTION: In some embodiments, histotripsy can be applied to a target tissue volume to lyse and solubilize the target tissue volume to release tumor antigens. In some embodiments, an immune response of the treatment can be evaluated. In other embodiments, an immune therapy can be applied after applying the histotripsy. In one embodiment, the lysed and solubilized cells can be extracted from the tissue. The extracted cells can be used to create immune therapies, including vaccines.SELECTED DRAWING: Figure 1
Owner:THE RGT UNIV OF MICHIGAN +1

Early intervention methods to prevent or ameliorate toxicity

Provided are methods for preventing or ameliorating toxicity caused by or due to a therapy, such as an immunotherapy or a cell therapy, by pre-emptive or early administration toxicity-targeting agent(s). In some embodiments, the therapy is a cell therapy in which the cells generally express recombinant receptors such as chimeric receptors, e.g., chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the methods, including the timing of the administration of the agents or treatments for toxicity, provide various advantages, such as lower toxicity while maintaining persistence and efficacy of the administered cells.
Owner:SEATTLE CHILDRENS HOSPITAL (DBA SEATTLE CHILDRENS RES INST)

Preparation and use of metalloproteinase-activated car-t structure

Preparation and use of a metalloproteinase-activated CAR-T structure. The present invention specifically relates to a conditionally activated chimeric antigen receptor comprising a TSAR regulatory element, an engineered immune cell, a preparation method therefor and a use thereof. By utilizing the characteristic of high expression of matrix metalloproteinase in a tumor microenvironment, an engineered immune cell product based on conditional activation can achieve immunotherapy which does not easily go off-target and has lower toxic side effects and higher safety.
Owner:ZHENGZHOU UNIV

Intratumoral immunotherapy with il-12 combined with CCL3

PCT designated stageWO2026080924A1ChemokinesPeptide/protein ingredientsCCL3Nucleotide
The invention relates to methods of treating a tumor in a subject by administering to the subject the following active agents: (a) interleukin- 12 (IL-12), a nucleotide expressing IL-12, or combinations thereof; and (b) c-c motif chemokine ligand 3 (CCL3), a nucleotide expressing CCL3, or combinations thereof. The invention also relates to therapeutic compositions that include the following active agents; (a) IL-12, a nucleotide expressing IL-12, or combinations thereof; and (b) CCL3, a nucleotide expressing CCL3, or combinations thereof.
Owner:TRUSTEES OF DARTMOUTH COLLEGE THE

Traditional Chinese medicine composition for treating colorectal tumor by regulating immune function and preparation method of traditional Chinese medicine composition

The invention provides a traditional Chinese medicine composition for treating colorectal tumor by regulating immune function. The invention further provides a traditional Chinese medicine extract and a preparation method thereof. The invention further provides a traditional Chinese medicine preparation. The invention further provides application of the traditional Chinese medicine composition, the traditional Chinese medicine extract or the traditional Chinese medicine preparation in preparation of medicines for treating colorectal tumor. According to the traditional Chinese medicine composition for treating the colorectal tumor by adjusting the immune function and the preparation method thereof, the prepared traditional Chinese medicine composition has the effects of supporting body resistance, invigorating spleen and tonifying kidney, clearing away heat and toxic materials, activating blood and removing stasis, tonifying qi and reinforcing vital essence, and removing stasis and food retention, and can be used for improving the immunosuppression microenvironment of the colorectal tumor in cooperation with chemotherapy drugs; the anti-tumor immune function of a colorectal tumor patient is improved, the tumor development is inhibited, and a new thought is provided for the immunotherapy of the colorectal tumor.
Owner:SHANGHAI PUTUO DISTRICT CENT HOSPITAL